About CARE

CARE is a collaborative effort against HIV/TB/HCV across the European region with a specific focus on the Russian Federation. It capitalises on already established European cohort networks and exploits extensive and longitudinal data and sample sets, both existing and prospectively collected. 

The specific research objectives of CARE are to:

Discover and validate novel soluble biomarkers reliably enabling the identification of treatment success of multidrug-resistant tuberculosis (MDR-TB) patients and to diagnose pulmonary tuberculosis.

Explore mechanisms explaining the susceptibility to develop extrapulmonary tuberculosis related to variants of the host gene SIGLEC1 that are also involved in response to HIV infection.

Analyse the correlation between drug-related variants in the tuberculosis genome and corresponding in-vitro drug susceptibility to develop a decision-making support tool for the choice of second line therapy in case of suspected MDR-TB.

Define epidemiology and pathways of drug-resistant HIV, including their relationship with HIV subtypes and TB coinfection, across the European Region including Russia, in order to better inform health policies and clinicians for an evidence-based introduction of integrase strand transfers inhibitors (INSTI) as part of first line antiretroviral therapy.

Discover and validate variants in the host genome influencing susceptibility to contracting AIDS and serious non-AIDS clinical events and adverse reactions to antiretroviral medicines in HIV-infected patients.

Compile experience for treating HCV infection by use of direct-acting antivirals from across Europe in order to inform best practice recommendations for how to use such medication in settings with current limited access and limited budgets.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter
CONTACTS

Francesca Incardona

 

f.incardona@euresist.org